Cellular effects of Everolimus and Sirolimus on podocytes

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Müller Krebs, Sandra ^a   Weber, Lena ^a   Tsobaneli, Julia ^a   Kihm, Lars P ^a   Reiser, Jochen ^b   Zeier, Martin ^a   Schwenger, Vedat ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; CYTOSKELETON; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NF-KAPPA B; PHOSPHORYLATION; PODOCYTES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; SYNAPTOPHYSIN; TOR SERINE-THREONINE KINASES;

EID: 84894151094     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080340     Document Type: Article

References (43)

1. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT et al. (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369: 756-758. doi:10.1038/369756a0. PubMed: 8008069.
2. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL et al. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457-468. doi:10.1016/S1097-2765(02)00636- 6. PubMed: 12408816. (Pubitemid 35284167)
3. Budde K, Becker T, Arns W, Sommerer C, Reinke P et al. (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of denovo kidney transplants: an open-label, randomised, controlled trial. Lancet 377: 837-847. doi:10.1016/S0140-6736(10)62318-5. PubMed: 21334736.
4. Keogh A (2004) Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 23: S202-S206. doi:10.1016/j.healun.2004.03.008. PubMed: 15093806.
5. Manito N, Rábago G, Palomo J, Arizón JM, Delgado J et al. (2011) Improvement in chronic renal failure after mycophenolate mofetil introduction and cyclosporine dose reduction: four-year results from a cohort of heart transplant recipients. Transplant Proc 43: 2699-2706. doi:10.1016/j.transproceed.2011.04.017. PubMed: 21911149.
6. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB et al. (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 931-940. doi:10.1056/NEJMoa021744. PubMed: 12954741. (Pubitemid 37064766)
7. Rubel JR, Milford EL, McKay DB, Jarcho JA (2004) Renal insufficiency and end-stage renal disease in the heart transplant population. J Heart Lung Transplant 23: 289-300. doi:10.1016/S1053-2498(03)00191-8. PubMed: 15019638. (Pubitemid 38333086)
8. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B et al. (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575. doi:10.1056/NEJMoa067411. PubMed: 18094377. (Pubitemid 350294223)
9. Flechner SM, Glyda M, Cockfield S, Grinyó J, Legendre Ch et al. (2011) The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 11: 1633-1644. doi:10.1111/j.1600-6143.2011.03573.x. PubMed: 21668635.
10. Durrbach A, Rostaing L, Tricot L, Ouali N, Wolf P et al. (2008) Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 85: 486-490. doi:10.1097/TP.0b013e318160d3c9. PubMed: 18301342.
11. Morelon E, Kreis H (2003) Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 35: 52S-57S. (Pubitemid 36547915)
12. Shankland SJ (2006) The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 69: 2131-2147. doi:10.1038/sj.ki.5000410. PubMed: 16688120.
13. Lebranchu Y, Thierry A, Thervet E, Büchler M, Etienne I et al. (2011) Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 11: 1665-1675. doi:10.1111/j.1600-6143.2011.03637.x. PubMed: 21797975.
14. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD et al. (2002) A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638. PubMed: 11856766. (Pubitemid 34183927)
15. Lannigan R (1962) Puromycin aminonucleoside nephrosis in rats: a progress report of acute and chronic experiments. Guys Hosp Rep 111: 378-387. PubMed: 13928692.
16. Eto N, Wada T, Inagi R, Takano H, Shimizu A et al. (2007) Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 72: 455-463. doi:10.1038/sj.ki.5002311. PubMed: 17457371. (Pubitemid 47237606)
17. Madhusudhan T, Wang H, Straub BK, Gröne E, Zhou Q et al. (2012) Cytoprotective signaling by activated protein C requires proteaseactivated receptor-3 in podocytes. Blood 119: 874-883. doi:10.1182/blood-2011-07-365973. PubMed: 22117049.
18. Kihm LP, Müller-Krebs S, Klein J, Ehrlich G, Mertes L et al. (2011) Benfotiamine Protects against Peritoneal and Kidney Damage in Peritoneal Dialysis. J Am Soc Nephrol 22: 914-926. doi:10.1681/ASN.2010070750. PubMed: 21511829.
19. Rico M, Mukherjee A, Konieczkowski M, Bruggeman LA, Miller RT et al. (2005) WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. Am J Physiol Renal Physiol 289: F431-F441. doi:10.1152/ajprenal.00389.2004. PubMed: 15798086. (Pubitemid 41003673)
20. Müller-Krebs S, Kihm LP, Madhusudhan T, Isermann B, Reiser J et al. (2012) Human RAGE antibody protects against AGE-mediated podocyte dysfunction. Nephrol Dial Transplant 27: 3129-3136. doi:10.1093/ndt/gfs005. PubMed: 22510380.
21. Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K et al. (2006) Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 8: 485-491. doi:10.1038/ncb1400. PubMed: 16622418.
22. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K et al. (2004) Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113: 1390-1397. doi:10.1172/JCI200420402. PubMed: 15146236. (Pubitemid 39071694)
23. Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L et al. (2001) Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 158: 1723-1731. doi:10.1016/S0002-9440(10)64128-4. PubMed: 11337370. (Pubitemid 32422937)
24. Huber TB, Kottgen M, Schilling B, Walz G, Benzing T (2001) Interaction with podocin facilitates nephrin signaling. J Biol Chem 276: 41543-41546. doi:10.1074/jbc.C100452200. PubMed: 11562357.
25. Asanuma K, Kim K, Oh J, Giardino L, Chabanis S et al. (2005) Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest 115: 1188-1198. doi:10.1172/JCI23371. PubMed: 15841212. (Pubitemid 40629037)
26. Zimmerman JJ, Kahan BD (1997) Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 37: 405-415. doi:10.1002/j.1552-4604.1997.tb04318.x. PubMed: 9156373. (Pubitemid 27215068)
27. Nashan B (2002) Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 11: 1845-1857. doi:10.1517/13543784.11.12.1845. PubMed: 12457444.
28. Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M et al. (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64: 36-42. doi:10.1097/00007890-199707150-00008. PubMed: 9233698. (Pubitemid 27327197)
29. Keller K, Daniel C, Schöcklmann H, Endlich KH, Kerjaschki D et al. (2006) Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 21: 2724-2735. doi:10.1093/ndt/gfl340. PubMed: 16861242. (Pubitemid 44542224)
30. Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C et al. (2009) Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 24: 630-638. PubMed: 18927120.
31. Vollenbröker B, George B, Wolfgart M, Saleem MA, Pavenstädt H et al. (2009) mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 296: F418-F426. PubMed: 19019920.
32. Kirchner GI, Winkler M, Mueller L, Vidal C, Jacobsen W et al. (2000) Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol 50: 449-454. PubMed: 11069439.
33. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB (2007) Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 25: 209-226. doi:10.1080/08977190701779101. PubMed: 18092230.
34. Gibbons JJ, Abraham RT, Yu K (2009) Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 36 (Suppl 3): S3-S17. doi:10.1053/S0093-7754(09) 00021-9. PubMed: 19963098.
35. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. doi:10.1126/science.1106148. PubMed: 15718470. (Pubitemid 40262113)
36. Yanagida-Asanuma E, Asanuma K, Kim K, Donnelly M, Young Choi H et al. (2007) Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes. Am J Pathol 171: 415-427. doi:10.2353/ajpath.2007.070075. PubMed: 17569780. (Pubitemid 47344675)
37. Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Péraldi MN et al. (2007) High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326-333. doi:10.2215/CJN.03751106. PubMed: 17699432.
38. Oroszlán M, Bieri M, Ligeti N, Farkas A, Meier B et al. (2010) Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 23: 125-132. doi:10.1016/j.trim.2010.05.003. PubMed: 20470887.
39. Munivenkatappa R, Haririan A, Papadimitriou JC, Drachenberg CB, Dinits-Pensy M et al. (2010) Tubular epithelial cell and podocyte apoptosis with de novo sirolimus based immunosuppression in renal allograft recipients with DGF. Histol Histopathol 25: 189-196. PubMed: 20017105.
40. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S et al. (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938. doi:10.1038/nm.1857. PubMed: 18724379.
41. Rehm B, Keller F, Mayer J, Stracke S (2006) Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 38: 711-713. doi:10.1016/j.transproceed.2006.01.052. PubMed: 16647451.
42. Carvalho C, Coentrão L, Bustorff M, Patrício E, Sampaio S et al. (2011) Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen. Clin Transplant 25: E401-E405. doi:10.1111/j.1399-0012.2011.01446.x. PubMed: 21457330.
43. Bohra R, Schöning W, Klawitter J, Brunner N, Schmitz V et al. (2012) Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat. PLOS ONE 7: e48063. doi:10.1371/journal. pone.0048063. PubMed: 23118926.